Today’s Stocks on Sale: FICO, AES, MRNA, and More
After dropping by 15.74% to close at $1,707.94 yesterday, the stock could continue to pull back today. Shares fell after William Pulte, a Federal Housing Finance Agency director, shared comments.Pulte wants the provider of credit scores to act more economically. He wanted to see the privatization of Fannie Mae (FNMA) and Freddie Mac (FMCC). The director’s negative comments on Fair Isaac experiencing a 15% increase in the last quarter hurt the stock.FICO stock still trades at a premium. The stock needs to fall further to fair value territory before it is a buy.AES lost nearly 10% on Wednesday. The firm signed two power purchase agreements with Meta Platforms (META). It will power Meta’s data centers with 650 MW in solar projects in Texas and Kansas. AES stock keeps falling after investors worry about potential subsidy cuts. The stock is in deep value territory that is due for a rebound. Its forward P/E is around five times.Moderna (MRNA) is at risk of erasing the stock rally on May 20. Sellers dumped the stock at $29.94 that day, and the stock has not recovered since then. The firm withdrew its flu/COVID-19 combo vaccine shot. However, it will resubmit the Biologics License Application for mRNA-1083 at the end of this year.Novavax (NVAX) risks falling, too. Short-sellers hold a 26.14% short interest in NVAX stock.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


